Pharmaceutical Intelligence
Analyst-grade briefs for pharma strategy, corporate development, and regulatory teams. 2,000 to 4,000 words per report, numbered ALL-CAPS sections, every claim cited with DOI / PMID / URL. Designed to read like a finished client deliverable, not a scaffold.
Short answer. Intelligence produces dated, cited, analyst-grade briefs across nine focus areas — pipeline, competitive, regulatory, patent, market size, deal flow, formulation technology, biomarker strategy, literature synthesis. Reports are date-grounded at request time so stale-cutoff content never reaches the deliverable.
Nine focus areas
- Pipeline & Clinical Stage Analysis — competitor trials, readout timing, trial design risk.
- Competitive Landscape — molecule / sponsor / indication coverage, differentiation gaps.
- Regulatory Intelligence — FDA AdCom, EMA CHMP, Health Canada, PMDA regulatory trend and precedent.
- Patent Landscape & IP Analysis — composition-of-matter, method claim, patent cliff and FTO considerations.
- Market Size & Commercial Opportunity — TAM, SAM, reimbursement precedent, patient population.
- Deal Flow & M&A Activity — public transactions, licensing, royalty structures.
- Formulation Technology Trends — modified release, complex generics, combination products.
- Biomarker & Companion Diagnostic Strategy — enrichment, stratification, regulatory pathway.
- Scientific Literature Synthesis — PubMed search grounded synthesis with PMID citations.
Citation standards
- Every factual claim cites a real source. Format:
Author et al., Year, Journal, Vol(Issue):Pages, DOI:xxx. - Bare
J Med Chem, 2020style citations are explicitly not acceptable. - Every clinical trial identifier appears as
NCT01234567 (verify at clinicaltrials.gov/NCT01234567). - No fabricated PMIDs, NCT IDs, DOIs, author names, or personal names.
- USD default currency; no CAD anchors.
Date grounding
Every Intelligence request injects today's date into the system prompt. The model's knowledge cutoff is declared explicitly (ICH-style "current as of {date}" framing). At least three citations per report must be to sources dated within the past 18 months or the report states "no verified post-cutoff source located" rather than silently serving stale content.
Follow-up conversation
After the brief renders, a follow-up panel opens carrying the full report as grounding context. Typical quick actions:
- Update with recent data (forces fresh citations).
- Dig deeper on the top competitor identified in the brief.
- What has changed since the last FDA Advisory Committee meeting in this therapeutic area.
- Draft the executive one-pager (180 words, three bullet points per section).
- Compare our positioning to the top competitor in the brief.
Frequently asked questions
What do Intelligence reports look like?
2,000 to 4,000 word briefs with numbered ALL-CAPS sections. Every claim cites a real source with DOI / PMID / URL and access date. Bare journal-year citations are not acceptable.
Which focus areas are supported?
Nine: Pipeline & Clinical Stage; Competitive Landscape; Regulatory Intelligence; Patent Landscape & IP; Market Size & Commercial; Deal Flow & M&A; Formulation Technology; Biomarker & Companion Diagnostic; Scientific Literature Synthesis.
How is staleness handled?
Reports are date-grounded at request time. Three-plus citations must be within the past 18 months, or the report says "no verified post-cutoff source located" rather than defaulting to stale data.
Is there a follow-up conversation mode?
Yes. After the report renders, a follow-up panel opens with the full brief as context. Quick actions include update with recent data, deeper competitor analysis, FDA AdCom changes, executive one-pager drafting, positioning comparison.